Gracell Starts China Trial of Allogenic CAR-T Candidate for ALL

Gracell Biotech, a Suzhou company developing novel CAR-T therapies, has started a clinical trial of GC027, a therapy that uses its off-the-shelf TruUCAR™ CAR-T technology, to treat patients with aggressive forms of acute lymphoblastic leukemia (ALL). GC027 is made of T cells from healthy donors, genetically edited by inserting a chimeric antigen receptor (CAR) ex vivo to bind and eliminate target T malignant cells. GC027 uses CRISPR genome editing, which is expected to avoid graft-versus-host disease (GvHD) as well as graft rejection. More details....

Share this with colleagues:

2